Genomics and the future of pharmacotherapy in psychiatry.

Genomics and the future of pharmacotherapy in psychiatry. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Genomics and the future of pharmacotherapy in psychiatry. Abstract Text:

Anil K Malhotra,Todd Lencz,Christoph U Correll,John M Kane,Anil K Malhotra,Todd Lencz,Christoph U Correll,John M Kane,

Pharmacogenetic studies of psychotropic drug response have focused on determining the relationship between variation in specific candidate genes and the positive and adverse effects of drug treatment. Preliminary evidence exists for a significant relationship between a promoter region polymorphism in the serotonin transporter gene and antidepressant response, as well as for associations between candidate neurotransmitter receptor genes and second generation antipsychotic drug response. More recent work in schizophrenia has focused on the use of first episode, antipsychotic naïve subjects, which may provide greater study power as suggested by studies examining dopamine receptor genetic variation and clinical response measures. An emerging body of literature suggests that pharmacogenetic strategies may be especially useful in the prediction of drug-induced adverse effects, in particular for the important side effect of antipsychotic-induced weight gain. New developments in genomics, including whole genome genotyping approaches and comprehensive information on genomic variation across populations, coupled with large-scale clinical trials in which DNA collection is routine, now provide the impetus for a next generation of pharmacogenetic studies. These increasingly comprehensive approaches should provide informative data on the genes associated with psychotropic drug response, a critical step towards the ultimate goal of 'personalized' medicine.

Genomics and the future of pharmacotherapy in psychiatry. Publishing Authors By Initials

AK Malhotra,T Lencz,CU Correll,JM Kane,AK Malhotra,T Lencz,CU Correll,JM Kane,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Genomics and the future of pharmacotherapy in psychiatry. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International review of psychiatry (Abingdon, Engl

VOLUME: 19

Page Numbers: 523-30

Journal Abbreviation:

ISSN: 0954-0261

DAY: 26

MONTH: Oct

YEAR: 2007

Genomics and the future of pharmacotherapy in psychiatry. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8918131

Genomics and the future of pharmacotherapy in psychiatry. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Genomics and the future of pharmacotherapy in psychiatry. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Genomics and the future of pharmacotherapy in psychiatry.

AFFILIATION: Division of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA. malhotra@lij.edu

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int Rev Psychiatry

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Genomics and the future of pharmacotherapy in psychiatry Related Publications

• 277.
• A modular, flexible training strategy to achieve competence in diagnostic and interventional musculoskeletal ultrasound in patients with hip osteoarthritis.
• A process to facilitate decision making in pediatric stem cell transplantation: the individualized care planning and coordination model.
• A role for N-cadherin in mesodermal morphogenesis during gastrulation.
• Advances and opportunities in assessing contaminant sensitivity of freshwater mussel (Unionidae) early life stages.
• Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor.
• Demonstration of complex-conjugate-resolved harmonic Fourier-domain optical coherence tomography imaging of biological samples.
• Diploids heterozygous for a vma13Delta mutation in Saccharomyces cerevisiae highlight the importance of V-ATPase subunit balance in supporting vacuolar acidification and silencing cytosolic V1-ATPase activity.
• Editorial: schizophrenia international research society.
• Effects of body mass on nicotine-induced thermogenesis and catecholamine release in male smokers.
• Genomics and the future of pharmacotherapy in psychiatry.
• Geriatrics as a paradigm for good chronic care.
• Head injury - modern army combatives: 999: may 30 2:40 PM - 3:00 PM.
• Integer quantum Hall effect on a six-valley hydrogen-passivated silicon (111) surface.
• Laparoscopic Nissen fundoplication in an infant with situs inversus.
• Loss of vacuolar proton-translocating ATPase activity in yeast results in chronic oxidative stress.
• Metabolic risks and effects of atypical antipsychotic treatment.
• National survey of pediatric residency program directors and residents regarding education in palliative medicine and end-of-life care.
• Patient-reported outcomes in end-of-life research in pediatric oncology.
• RAVE is essential for the efficient assembly of the C subunit with the vacuolar H(+)-ATPase.
• Radiation medicine practice in the image-guided radiation therapy era: new roles and new opportunities.
• Raftlike polyvalent inhibitors of the anthrax toxin: modulating inhibitory potency by formation of lipid microdomains.
• Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
• SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells.
• Scaffolds based on degradable alginate hydrogels and poly(lactide-co-glycolide) microspheres for stem cell culture.
• Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid.
• The contributions of strategy use to working memory span: a comparison of strategy assessment methods.
• The management of schizophrenia: safety, treatment, and continuity of care. Introduction.
• Treatment adherence and long-term outcomes.
• Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?